IADR Abstract Archives
Guided Bone Regeneration Biologically Transformed Multicomponent Graft
Objectives: This clinical study aims to develop a method for repairing jawbone defects using a biologically transformable multicomponent graft (MG).
Methods: There were 26 patients under observation: 15 in the control group (A) and 11 in the experimental group (B). Both groups used biomaterials from Botiss GmbH: an osteoconductive graft, Cerabone® (OG), and a resorbed membrane, Jason® (RM). In Group A, augmentation of the bone defect was performed by guided bone regeneration with OG and RM. In Group B, the bone defects were treated by guided bone regeneration augmented with an MG. MG was prepared using the method of lipid aspiration from adipose tissue of the anterior abdominal wall. Mesenchymal stem cells (MSCs) were isolated enzymatically and placed in an incubator to increase the cell mass's numerical volume. The OG was preliminarily cleaned from fine dust and air bubbles in an ultrasonic bath. On the day of surgery, autologous platelet-rich fibrin (PRF) was isolated and pooled in autologous blood serum with MSCs and OG. The resulting MG was placed in the bone defect. In both groups, biotransformation was monitored using cone-beam computed tomography (CBCT) and X-ray parameterization.
Results: The reorganization of OG in the MG stimulated the growth of bone throughout the graft augmentation area. CBCT and x-ray parameterization showed qualitative differences in augmentation and biotransformation in both groups six months and one year later. In Group B, the biotransformation of augmenting bone lasted throughout the volume of the defect. In Group A, the MG retained the same density.
Conclusions: CBCT and parameterization of the x-ray image show that the areas of biotransformation of the MG in Group B are comparable with the fields of healthy bone. The transformation of MG is much faster. The bone structure is formed throughout the thickness of the augmentation.
Methods: There were 26 patients under observation: 15 in the control group (A) and 11 in the experimental group (B). Both groups used biomaterials from Botiss GmbH: an osteoconductive graft, Cerabone® (OG), and a resorbed membrane, Jason® (RM). In Group A, augmentation of the bone defect was performed by guided bone regeneration with OG and RM. In Group B, the bone defects were treated by guided bone regeneration augmented with an MG. MG was prepared using the method of lipid aspiration from adipose tissue of the anterior abdominal wall. Mesenchymal stem cells (MSCs) were isolated enzymatically and placed in an incubator to increase the cell mass's numerical volume. The OG was preliminarily cleaned from fine dust and air bubbles in an ultrasonic bath. On the day of surgery, autologous platelet-rich fibrin (PRF) was isolated and pooled in autologous blood serum with MSCs and OG. The resulting MG was placed in the bone defect. In both groups, biotransformation was monitored using cone-beam computed tomography (CBCT) and X-ray parameterization.
Results: The reorganization of OG in the MG stimulated the growth of bone throughout the graft augmentation area. CBCT and x-ray parameterization showed qualitative differences in augmentation and biotransformation in both groups six months and one year later. In Group B, the biotransformation of augmenting bone lasted throughout the volume of the defect. In Group A, the MG retained the same density.
Conclusions: CBCT and parameterization of the x-ray image show that the areas of biotransformation of the MG in Group B are comparable with the fields of healthy bone. The transformation of MG is much faster. The bone structure is formed throughout the thickness of the augmentation.